Novel Molecular Insights and Evolution of Less Toxic Therapeutic Strategies in Burkitt Lymphoma.

Cancers (Basel) · 2025 · PMC12564111 · PMID 41154426

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In a retrospective analysis of 80 adults with BL treated with CODOX/M-IVAC with or without rituximab, a trend of improved 3-PFS (74% versus 61%) and 3-OS (77% versus 66%) was observed under rituximab-containing therapy, although results did not reach statistical significance [ 94 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.